Category Specific RSS

News

OncoSil Gains Momentum in Germany as 120 Hospitals Secure Negotiation Rights

The fight against pancreatic cancer has taken a step forward in Germany, with 120 hospitals now legally entitled to negotiate…

2 years ago

Optiscan Advances GI Imaging with New Study in Germany

Tackling a Major Health Challenge Gastrointestinal (GI) diseases, including colorectal cancer, are a significant global health issue. In 2020 alone,…

2 years ago

December 2024 quarter CPI has interest rate doves cooing

Slightly below expectations December 2024 quarter CPI data released today were warmly received by stock market investors. The stats, which…

2 years ago

Harris Technology sees big opportunity for refurbished tech in 2025 with positive cash flow

Amid a challenging retail landscape that has seen the collapse of major players like Catch, Harris Technology (ASX: HT8) has…

2 years ago

OncoSil Medical strengthens board with appointment of governance expert

In a strategic move to bolster its governance and corporate strategy, OncoSil Medical Limited (ASX:OSL), a leader in pancreatic cancer…

2 years ago

Mesoblast RYONCIL® Therapy Approved by FDA

RYONCIL® (remestemcel-L) becomes the first mesenchymal stromal cell (MSC) product approved by the US Food and Drug Administration (FDA) for…

2 years ago

The RBA’s benchmark interest rate remains unchanged at 4.35%

Calls from some quarters for the RBA to slip an interest rate cut into borrowers’ Christmas stockings have gone unheeded,…

2 years ago

AML3D Secures A$2.27M Contract with Tennessee Valley Authority to Expand US Presence

“This ARCEMY® X order from the TVA is very much aligned with the US Scale Up growth strategy we have…

2 years ago

Australia’s GDP limps higher in September 2024 quarter

Australia’s economic growth, as measured by the ABS-compiled chain volume GDP statistics that adjust for price increases, rose by a…

2 years ago

Invion doses first patient in phase I/II non-melanoma skin cancer trial

Invion (ASX:IVX) surged higher after announcing that it had completed the dosing of the first patient in its Phase I/II…

2 years ago